Skip to Content
MilliporeSigma
  • Cell therapy in reperfused acute myocardial infarction does not improve the recovery of perfusion in the infarcted myocardium: a cardiac MR imaging study.

Cell therapy in reperfused acute myocardial infarction does not improve the recovery of perfusion in the infarcted myocardium: a cardiac MR imaging study.

Radiology (2014-03-13)
Lourens F H J Robbers, Robin Nijveldt, Aernout M Beek, Alexander Hirsch, Anja M van der Laan, Ronak Delewi, Pieter A van der Vleuten, René A Tio, Jan G P Tijssen, Mark B M Hofman, Jan J Piek, Felix Zijlstra, Albert C van Rossum
ABSTRACT

To investigate the effects of cell therapy on myocardial perfusion recovery after treatment of acute myocardial infarction (MI) with primary percutaneous coronary intervention (PCI). In this HEBE trial substudy, which was approved by the institutional review board (trial registry number ISRCTN95796863), the authors assessed the effects of intracoronary infusion with bone marrow-derived mononuclear cells (BMMCs) or peripheral blood-derived mononuclear cells (PBMCs) on myocardial perfusion recovery by using cardiac magnetic resonance (MR) imaging after revascularization. In 152 patients with acute MI treated with PCI, cardiac MR imaging was performed after obtaining informed consent-before randomization to BMMC, PBMC, or standard therapy (control group)-and repeated at 4-month follow-up. Cardiac MR imaging consisted of cine, rest first-pass perfusion, and late gadolinium enhancement imaging. Perfusion was evaluated semiquantitatively with signal intensity-time curves by calculating the relative upslope (percentage signal intensity change). The relative upslope was calculated for the MI core, adjacent border zone, and remote myocardium. Perfusion differences among treatment groups or between baseline and follow-up were assessed with the Wilcoxon signed rank or Mann-Whitney U test. At baseline, myocardial perfusion differed between the MI core (median, 6.0%; interquartile range [IQR], 4.1%-8.0%), border zone (median, 8.4%; IQR, 6.4%-10.2%), and remote myocardium (median, 12.2%; IQR, 10.5%-15.9%) (P < .001 for all), with equal distribution among treatment groups. These interregional differences persisted at follow-up (P < .001 for all). No difference in perfusion recovery was found between the three treatment groups for any region. After revascularization of ST-elevation MI, cell therapy does not augment the recovery of resting perfusion in either the MI core or border zone.

MATERIALS
Product Number
Brand
Product Description

Meglumine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Meglumine, 99.0-100.5% dry basis, meets USP testing specifications
Supelco
Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
N-Methyl-D-glucamine, 99.0-100.5% (titration)
Sigma-Aldrich
N-Methyl-D-glucamine, ReagentPlus®, ≥99.0% (T)